🟠 Moderate Evidence
The epidemiological profile of chronic kidney disease (CKD) in the United States is undergoing a significant shift, with diabetes-related kidney damage now accounting for a growing proportion of cases, even as the overall prevalence of CKD remains stubbornly stable. According to data presented in a 2026 analysis, approximately 1 in 7 U.S. adults—roughly 15%—lived with CKD in both 2013 and 2023, suggesting that while the total burden has plateaued, the composition of disease has changed markedly over the decade.
Key takeaways
- Overall CKD prevalence in US adults remained stable at approximately 15% (1 in 7) between 2013 and 2023
- Diabetes-linked CKD is rising as a proportion of total cases, reflecting the growing diabetes epidemic in the US population
- Most individuals with CKD remain undiagnosed, unaware their kidney function is declining and their cardiovascular risk is elevated
- The shift underscores the need for earlier screening and stricter glycaemic control in at-risk populations
CKD Prevalence Stability Masks Compositional Shift Toward Diabetes-Related Disease
Proportion of CKD cases, United States, 2013 vs 2023. Overall rate stable, but diabetes-linked cases rising.
Source: 2026 US epidemiological analysis | Georgian Medical Journal News
The paradox: stable total disease burden, shifting underlying cause
While the headline prevalence of CKD has remained unchanged at roughly 15% of the adult US population over the past decade, the disease is no longer distributed uniformly across its traditional risk groups. Diabetes-related chronic kidney disease—medically termed diabetic kidney disease (DKD)—is now accounting for an expanding share of the CKD burden, reflecting the parallel trajectory of type 2 diabetes, which affects approximately 11.3% of the US population according to the CDC. This compositional shift has important implications for prevention strategy and clinical practice.
The stability in overall CKD prevalence does not indicate disease control or improved kidney function across the population. Rather, it suggests that improvements in some areas—such as better blood pressure management or reductions in certain forms of glomerulonephritis—may be offset by rising incidence of DKD driven by increasing diabetes prevalence and obesity rates. Clinical practice must adapt to this evolving demographic, prioritizing glycaemic and blood pressure control in diabetic patients as the primary lever for halting DKD progression.
The silent epidemic: most people remain unaware of their kidney disease
CKD is frequently called a “silent killer” because the condition progresses without symptoms until advanced stages, at which point irreversible kidney damage may have already occurred. According to the 2026 analysis, the vast majority of individuals living with CKD do not realize they have the condition, creating a diagnostic and therapeutic gap. This lack of awareness has serious health consequences: CKD sharply elevates the risk of myocardial infarction, stroke, kidney failure requiring dialysis or transplantation, and premature death.
Early detection through routine screening—particularly in high-risk populations such as adults with diabetes, hypertension, or a family history of kidney disease—could enable earlier intervention with ACE inhibitors, angiotensin-receptor blockers, or sodium-glucose cotransporter-2 (SGLT2) inhibitors, all of which have demonstrated benefit in slowing DKD progression. Public health policy and clinical guidelines increasingly recognize the importance of earlier case identification and treatment initiation to prevent progression to end-stage renal disease.
Diabetes as the dominant driver: understanding the shift
The rise in diabetes-linked CKD as a proportion of total CKD cases reflects both the absolute increase in diabetes prevalence and the fact that diabetic patients face high risk of kidney damage when glycaemic control is suboptimal. Type 2 diabetes, which accounts for approximately 90–95% of all diabetes cases in the US, frequently coexists with hypertension and obesity—a triad that substantially accelerates kidney disease development. The 2026 epidemiological findings suggest that unless diabetes incidence is reduced or glycaemic outcomes improve, the proportion of CKD attributable to diabetes will likely continue to grow, even if the absolute number of CKD cases remains stable.
Roughly 1 in 7 U.S. adults—about 15%—had CKD in 2013, and approximately 1 in 7 still had it in 2023, but the type of kidney disease has fundamentally changed, with diabetes-linked cases now comprising an increasing share.
— 2026 US epidemiological analysis
What this means
Frequently asked questions
Why is CKD called “silent”?
Because kidney disease typically causes no symptoms until kidney function has declined severely. By the time a person experiences fatigue, nausea, or swelling—hallmark CKD symptoms—permanent damage has often occurred. This is why screening in high-risk populations (diabetes, hypertension, family history) is so important: it catches disease early, before symptoms appear, allowing preventive treatment to begin.
What blood tests detect CKD?
The two primary tests are serum creatinine (to estimate glomerular filtration rate, or eGFR) and urine albumin-to-creatinine ratio (uACR). An eGFR below 60 mL/min/1.73 m² or urine albumin exceeding 30 mg/g creatinine indicates kidney damage. Annual screening is recommended for all adults with diabetes or hypertension, beginning no later than age 40.
Can diabetes-related kidney disease be reversed?
Early-stage diabetic kidney disease can be slowed or halted with aggressive blood sugar and blood pressure control and newer medications such as SGLT2 inhibitors, which have shown remarkable efficacy in reducing albuminuria and preserving kidney function. However, advanced kidney disease (stage 4–5 CKD) is generally irreversible, making early detection and intervention critical.
As the US population ages and diabetes prevalence continues to rise, the burden of diabetes-related CKD will likely intensify. The stable overall prevalence of CKD over the past decade masks a troubling reality: the disease is becoming increasingly concentrated in a population—diabetic adults—who stand to benefit most from intensive, coordinated prevention and management strategies. Healthcare systems that prioritize early screening, robust glycaemic control, and timely initiation of renoprotective therapy will be best positioned to prevent the progression of CKD to end-stage renal disease and reduce the substantial cardiovascular and mortality burden that accompanies chronic kidney disease.
Source: Kidney disease profile shifts: Diabetes-linked CKD rises as overall US rate stalls
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
